Long-term treatment with vigabatrin – 10 years of clinical experience  by Ylinen, Aarne et al.
Article No. seiz.1998.0260, available online at http://www.idealibrary.com on
Seizure 1999; 8: 181–183
Long-term treatment with vigabatrin – 10 years of
clinical experience
Aarne Ylinen†, Tuuli Salmenpera¨, John P. Mumford§ & Paavo J. Riekkinen†
Department of Neurology and †A.I. Virtanen Institute, University of Kuopio, Kuopio, Finland;
§Consultant in Pharmaceutical Medicine, Formerly Marion Merrell Ltd UK, Winnersh, Berkshire, UK
Correspondence to: Dr Aarne Ylinen, Department of Neurology, University of Kuopio, POB 1627, SF-70211 Kuopio,
Finland
This report describes the long-term follow-up of 56 patients with refractory partial epilepsy who, within 3 months of vigabatrin
add-on therapy (3 g/day), showed a reduction in monthly seizure frequency of more than 50%. The short-term (6 months) and
long-term (5 years) effects of vigabatrin on seizure frequency in this patient cohort have been published separately. The reduction
in seizure frequency appeared to be long-lasting in the patients followed-up .n D 36/ and, importantly, a significant number of
the patients .n D 7/ became seizure-free, especially during long-term treatment. Thus, the efficacy of vigabatrin appears to be
progressive, at least in patients who show an early response to treatment. These results are consistent with experimental findings
that suggest that vigabatrin may have anti-epileptogenic and neuroprotective effects.
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Vigabatrin is effective as an add-on therapy in approxi-
mately 50% of patients with refractory partial epilepsy,
and a prolonged therapeutic response has been ob-
served in the majority of responders1–3. When used
as monotherapy, vigabatrin has proved to be as suc-
cessful as carbamazepine4. However, failure of carba-
mazepine monotherapy is usually due to the occurrence
of side-effects; whereas for vigabatrin, treatment fail-
ure is more often due to a lack of efficacy. Vigabatrin
monotherapy has been shown to be well tolerated, par-
ticularly in its lack of effects on cognitive function4.
In preclinical research, vigabatrin has been found to
inhibit the development of kindling, suggesting a po-
tential anti-epileptogenic effect of this drug5. Further-
more, vigabatrin has been shown to protect neurons and
neuronal function during prolonged, experimentally-
induced seizures6.
To study the clinical relevance of these experimen-
tal findings, the long-term outcome of epilepsy was
analysed in patients who originally responded to vi-
gabatrin add-on therapy. A retrospective approach was
adopted because of the difficulties inherent in compara-
tive group studies over periods as long as 10 years. The
hypothesis was that if vigabatrin prevents cellular dam-
age during epileptic seizures and slows epileptogene-1059–1311/99/030181 + 03 $12.00/0sis, then vigabatrin-treated patients should improve, or
have a better prognosis than refractory patients treated
by conventional antiepilepsy drugs (AEDs).
Materials and Methods
This retrospective study was performed on a cohort
of patients selected from two studies of add-on vigaba-
trin therapy which were started approximately 11 years
ago at the University Hospital of Kuopio, Finland. The
original population of this study comprised 56 drug-
refractory epilepsy patients (including 12 patients with
a severe mental handicap). These patients had shown a
response to treatment with vigabatrin 3 g/day (defined
as a greater than 50% reduction in monthly seizure fre-
quency within 3 months) and had received long-term
treatment with the drug. The short-term and long-term
efficacy of the treatments, and a detailed description
of the patient populations, have been published else-
where3, 7, 8.
Patients included in the analysis received vigaba-
trin treatment throughout the follow-up period. They
also received their primary epilepsy management at
the study clinic and had medical records available for
data abstraction. Patients who discontinued the study
or failed to respond (as defined above) were excluded,c© 1999 BEA Trading Ltd
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Fig. 1: Numbers of patients followed for 10 years receiving
one, two and three AEDs before initiating vigabatrin therapy
and at year 10.
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Fig. 2: Effect of add-on vigrabatrin on mean monthly seizure
frequency.as were patients referred to other clinics, patients who
received epilepsy surgery during the long-term treat-
ment period and patients who did not have continu-
ous epilepsy management at the study clinic. Clinical
assessments included dose of vigabatrin, concomitant
AEDs, number of seizures per month, occurrence of
adverse events, and concurrent disease states.
A summary and descriptive statistical analyses were
then completed, comparing baseline information with
that obtained after 6 and 10 years of continuous viga-
batrin treatment. SPSS/PC+ was used to perform the
statistical analyses.
Results
Thirty-six of the 56 patients with uncontrolled epilepsy
who showed a response within 3 months of vigaba-
trin add-on therapy continued to receive treatment for
6 years and had readily available medical records.
Twenty-four patients were still receiving vigabatrin af-
ter 10 years. However, four of these patients underwent
surgery after the first long-term treatment evaluation
point (at 6 years) and were therefore excluded from the
10-year evaluation.
The median dose of vigabatrin received by patients
was 3 g/day (range 1.5–5 g/day). A decrease in the num-
ber of concurrent AEDs was noted in patients followed
for 6 years. Before initiating vigabatrin therapy 9, 19,
and 8 patients were receiving one, two, or three AEDs
respectively. At the 6-year follow-up evaluation 11, 21,
and 4 patients were receiving one, two, or three AEDs
respectively. The corresponding values for the patients
followed-up for 10 years are illustrated in Fig. 1. There
were no major changes in concurrent AEDs between
the 6- and 10-year evaluation points.
The mean monthly seizure frequency was signifi-
cantly higher at baseline than after 6 years (P < 0:001,
paired t-test) or 10 years .P < 0:01/ of treatment. The
patients who were evaluated after 6 years of vigabatrin
therapy had a mean of 14.3 seizures per month at base-
line. This value decreased to 5.0 after 3 months of viga-
batrin treatment and to 4.9 after 6 years. The patients
evaluated during the 10-year treatment period had a
mean of 14.7 seizures per month during the baseline pe-
riod. With vigabatrin treatment, the seizure frequency
fell progressively to 5.0 seizures after 3 months, to 2.6
after 6 years and to 3.7 after 10 years (Fig. 2). Six pa-
tients became seizure-free during the 6-year long-term
treatment period. Between the 6- and 10-year follow-
up points, an additional patient became seizure-free and
three had a marked reduction in seizures, with freedom
from seizures in some months. One patient, who was
seizure-free at 6 years, experienced a subsequent dete-
rioration in seizure control.Seven of the 36 patients reported side-effects at the
6-year visit compared with four patients at baseline.
Two of the 20 patients evaluated at baseline and at
10 years reported side-effects. Two patients were di-
agnosed with lupus erythematosus disseminatus dur-
ing the follow-up period of 6 years. One mentally re-
tarded patient became psychotic and improved after
the reduction of vigabatrin dose and the introduction
of neuroleptics. An additional patient had reversible
behavioural problems. Two mentally retarded patients
were reported to improve behaviourally compared with
baseline. One patient was diagnosed with arterial hy-
pertension and appropriate medication was introduced.
Discussion
In this study, administration of vigabatrin as an add-on
therapy significantly reduced the mean monthly seizure
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Journal 1997; 314: 180–181.frequency during long-term follow-up of the patient co-
hort. Although the mean seizure frequency decreased
during the first 3 months of treatment, the number of pa-
tients who were completely free of seizures increased
from one after 3 months to seven after 10 years. This
proportion is much higher than could be expected in
the population of patients shown to be refractory to
conventional epilepsy treatments.
The findings of this study are consistent with those
of Tartara et al9. They followed-up four patients whose
dose of vigabatrin, or concomitant medication did not
change over 78 months. These previously refractory pa-
tients, who had been having 5–10 seizures per month
for several years before vigabatrin treatment, showed a
progressive decline in seizure frequency. Two patients
became seizure-free after 8 and 12 months respectively,
and the other two patients showed a decline in seizure
frequency throughout the study period, with freedom
from seizures in some months. These results tend to
support the findings of this study, and suggest a mech-
anism whereby vigabatrin depresses the tendency for
one seizure to trigger further seizures.
The conclusions drawn from uncontrolled studies of
add-on therapy have certain limitations10. Nonetheless,
the number of previously refractory patients who be-
come totally seizure-free during long-term follow-up
is a reliable end-point. All the patients in this study
had suffered from epilepsy for more than 5 years and
most had had epilepsy for more than 10 years. This
means that they had only a minimal chance of achiev-
ing seizure-free status with their conventional medi-
cations11. Alternatively, the reduction in seizure fre-
quency may simply be a function of the natural history
of the disease, though this seems unlikely and has not
been described before. A further explanation is that
fewer seizures with any drug will mean fewer seizures
in the future. Again, this has not been described with
other drugs and therefore may also be excluded.
The fact that vigabatrin may affect peripheral vision
had not been reported when this study was being carried
out12. The visual fields of those patients still receiving
vigabatrin are currently being evaluated. The final re-
port concerning the visual fields of vigabatrin-treated
patients at our centre is in preparation.
The results of this study suggest that the efficacy of
vigabatrin increases progressively, at least in patients
who show an early response to vigabatrin treatment. In
addition, other studies have shown that vigabatrin does
not impair cognitive function4. These results may be
related to the experimental findings that vigabatrin is
anti-epileptogenic5 and neuroprotective6. However, thepotential risk of visual field constriction should prompt
the physician to evaluate the benefits and risks of viga-
batrin for each patient and follow them up adequately
with regular visual field examinations, even if they are
asymptomatic.
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